Dae-Won Park1, Seong-Hyun Park2, Sung-Kyoo Hwang1. 1. Department of Neurosurgery, School of Medicine, Kyungpook National University, 130 Dongdeok-ro, Jung-gu, Daegu, 41944, South Korea. 2. Department of Neurosurgery, School of Medicine, Kyungpook National University, 130 Dongdeok-ro, Jung-gu, Daegu, 41944, South Korea. nsdoctor@naver.com.
Abstract
PURPOSE: Increased serum biomakers, such as S100 calcium-binding protein B (S100B) and neuron-specific enolase (NSE), are associated with traumatic brain injury (TBI). The purpose of this study is to investigate the serum levels of S100B and NSE in pediatric TBI patients and to predict a clinical outcome. METHODS: Peripheral venous blood was collected within 6 h of injury and at 1 week to measure S100B and NSE. The serum S100B and NSE levels were measured using commercially available enzyme-linked immunosorbent assay kits. The authors divided participants into two groups at admission: a favorable group (patients with Glasgow Coma Scale [GCS] scores of 10-15) and an unfavorable group (patients with GCS scores of less than 9). Both S100B and NSE levels were compared between the two groups at the time of admission and 1 week later. RESULTS: Ten pediatric patients were enrolled (5 in the favorable group, 5 in the unfavorable group). The median serum S100B level of 134.21 pg/ml (range, 51.00-789.65 pg/ml) in patients with TBI at admission dropped to 41.49 pg/ml (range, 25.65-260.93 pg/ml) after 1 week, with significant differences between the traumatic event and 1 week later (p = 0.007). The median serum NSE level of 14.76 ng/ml (range, 6.48-21.23 ng/ml) in patients with TBI at admission was higher than that after 1 week (4.96 ng/ml, range, 3.01-31.21 ng/ml), with significant differences (p = 0.015). A significant difference was observed in S100B after 1 week between patients in the favorable and unfavorable groups (p = 0.047). One patient whose serum S100B and NSE levels were elevated 1 week after TBI eventually died. CONCLUSIONS: Elevated serum S100B and NSE levels in pediatric TBI patients decreased 1 week after traumatic events. The serum S100B level 1 week after TBI was related to the severity of brain damage. These results indicated that serum S100B and NSE might play a role in predicting the prognosis and monitoring ongoing brain injury in pediatric TBI patients.
PURPOSE: Increased serum biomakers, such as S100 calcium-binding protein B (S100B) and neuron-specific enolase (NSE), are associated with traumatic brain injury (TBI). The purpose of this study is to investigate the serum levels of S100B and NSE in pediatric TBI patients and to predict a clinical outcome. METHODS: Peripheral venous blood was collected within 6 h of injury and at 1 week to measure S100B and NSE. The serum S100B and NSE levels were measured using commercially available enzyme-linked immunosorbent assay kits. The authors divided participants into two groups at admission: a favorable group (patients with Glasgow Coma Scale [GCS] scores of 10-15) and an unfavorable group (patients with GCS scores of less than 9). Both S100B and NSE levels were compared between the two groups at the time of admission and 1 week later. RESULTS: Ten pediatric patients were enrolled (5 in the favorable group, 5 in the unfavorable group). The median serum S100B level of 134.21 pg/ml (range, 51.00-789.65 pg/ml) in patients with TBI at admission dropped to 41.49 pg/ml (range, 25.65-260.93 pg/ml) after 1 week, with significant differences between the traumatic event and 1 week later (p = 0.007). The median serum NSE level of 14.76 ng/ml (range, 6.48-21.23 ng/ml) in patients with TBI at admission was higher than that after 1 week (4.96 ng/ml, range, 3.01-31.21 ng/ml), with significant differences (p = 0.015). A significant difference was observed in S100B after 1 week between patients in the favorable and unfavorable groups (p = 0.047). One patient whose serum S100B and NSE levels were elevated 1 week after TBI eventually died. CONCLUSIONS: Elevated serum S100B and NSE levels in pediatric TBI patients decreased 1 week after traumatic events. The serum S100B level 1 week after TBI was related to the severity of brain damage. These results indicated that serum S100B and NSE might play a role in predicting the prognosis and monitoring ongoing brain injury in pediatric TBI patients.
Authors: Rachel Pardes Berger; Michael C Bazaco; Amy K Wagner; Patrick M Kochanek; Anthony Fabio Journal: Dev Neurosci Date: 2010-09-18 Impact factor: 2.984
Authors: Nicola Marchi; Peter Rasmussen; Miranda Kapural; Vince Fazio; Kelly Kight; Marc R Mayberg; Andrew Kanner; Barbara Ayumar; Ben Albensi; Marco Cavaglia; Damir Janigro Journal: Restor Neurol Neurosci Date: 2003 Impact factor: 2.406
Authors: Derek J Roberts; Richard I Hall; Yan Wang; Lisa C Julien; Jeremy Wood; Kerry B Goralski Journal: Can J Anaesth Date: 2021-09-27 Impact factor: 6.713
Authors: Jamie Kearns; Aisling M Ross; Darragh R Walsh; Rachel M Cahalane; Rita Hinchion; Maria C Ryan; Elaine Conway; Tom M Comyns; Ian C Kenny; Eibhlís M O'Connor; Kieran D McGourty; John Joseph Eugene Mulvihill Journal: BMJ Open Sport Exerc Med Date: 2020-11-26
Authors: Birte Weber; Ina Lackner; Christian Karl Braun; Miriam Kalbitz; Markus Huber-Lang; Jochen Pressmar Journal: Front Pediatr Date: 2021-03-16 Impact factor: 3.418
Authors: Andreas Totzeck; Benjamin Stolte; Kathrin Kizina; Saskia Bolz; Melina Schlag; Andreas Thimm; Christoph Kleinschnitz; Tim Hagenacker Journal: Int J Mol Sci Date: 2019-10-30 Impact factor: 5.923